Peptide library

Commonly reported vial sizes, reconstitution volumes and dosing schedules, with sources.

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Single peptides

5-Amino-1MQ

NNMT inhibitor (small molecule)

5-Amino-1MQ is a small, cell-permeable molecule studied as a selective inhibitor of the enzyme NNMT (nicotinamide N-methyltransferase).

10 mg vial · Once or twice daily, subcutaneous or oral

Abaloparatide

Parathyroid hormone-related peptide analog (PTHrP 1-34)

Abaloparatide is a PTHrP analog that is FDA-approved for osteoporosis in postmenopausal women and in men at high fracture risk.

3 mg vial · Once daily in the labeled regimen and in cited trials

Adipotide

Adipose-vasculature-targeting proapoptotic peptidomimetic

Adipotide is an experimental peptide-like compound designed to deliver a cell-death signal to the blood vessels that feed white fat.

5 mg vial · Once daily, subcutaneous

AICAR

AMPK-activating adenosine analogue (nucleoside)

AICAR is a nucleoside that the body converts into an AMP mimic, used in research as a pharmacological activator of AMPK.

50 mg vial · Once daily, subcutaneous

AOD-9604

Modified fragment of human growth hormone (residues 177-191)

AOD-9604 is a 16-amino-acid fragment of the tail of human growth hormone that was developed as an obesity candidate.

5 mg vial · Once daily, subcutaneous (commonly reported in the morning)

ARA-290

Erythropoietin-derived innate repair receptor agonist peptide

Derived from a region of erythropoietin, ARA-290 (cibinetide) is a short synthetic peptide built to engage tissue-protective receptors without stimulating red-cell production.

10 mg vial · Once daily, subcutaneous

BPC-157

Synthetic pentadecapeptide

BPC-157 is a synthetic peptide derived from a sequence found in gastric juice.

5 mg vial · Once daily, subcutaneous (some reports split it into two injections)

Bronchogen

Synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Leu)

Bronchogen is a four-residue peptide (alanine, glutamate, aspartate, leucine) studied by the Khavinson group as a regulator of airway tissue.

20 mg vial · Once daily, in 10- or 20-day courses (community-reported)

Cagrilintide

Long-acting amylin analogue

Cagrilintide is an acylated analogue of the hormone amylin, studied as a once-weekly appetite-regulating agent.

5 mg vial · Once weekly, subcutaneous

Cardiogen

Synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Arg)

Cardiogen is a four-residue peptide (alanine, glutamate, aspartate, arginine) associated with heart tissue in the Khavinson bioregulator literature.

20 mg vial · Once daily, subcutaneous (courses of up to about 12 weeks, community-reported)

Cartalax

Synthetic tripeptide bioregulator (Ala-Glu-Asp)

Cartalax is a three-residue peptide (alanine, glutamate, aspartate) studied by the Khavinson group in connection with cartilage and connective tissue.

20 mg vial · Once daily, subcutaneous (8-12 week courses, community-reported)

Chonluten

Synthetic tripeptide bioregulator (Glu-Asp-Gly)

Chonluten is a three-residue peptide (glutamate, aspartate, glycine) described by the Khavinson group in connection with airway and lung tissue.

20 mg vial · Once daily, subcutaneous (gradual escalation over 8-16 weeks, community-reported)

CJC-1295 (No DAC)

Growth hormone releasing hormone analog

CJC-1295 without DAC (also called Mod GRF 1-29) is a growth-hormone releasing hormone analog.

5 mg vial · Once daily, commonly at bedtime (some reports use 1-3x daily), subcutaneous

CJC-1295 (With DAC)

Long-acting growth hormone releasing hormone analog

CJC-1295 with DAC is a long-acting GHRH analog engineered to bind serum albumin, giving a half-life of days rather than minutes.

5 mg vial · Twice weekly (once weekly also described)

Cortagen

Synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Pro)

Cortagen is a four-residue peptide (alanine, glutamate, aspartate, proline) studied by the Khavinson group as a brain-oriented bioregulator.

20 mg vial · Once daily, subcutaneous (4-week courses, community-reported)

DSIP

Endogenous neuropeptide (nonapeptide)

DSIP is a small naturally occurring neuropeptide first isolated from rabbit brain and studied for links to sleep regulation.

5 mg vial · Once daily in the evening, subcutaneous

Eloralintide

Selective amylin receptor agonist

Eloralintide is an investigational amylin receptor agonist from Eli Lilly being developed as a once-weekly obesity therapy.

10 mg vial · Once weekly, subcutaneous

Epitalon

Synthetic tetrapeptide (Ala-Glu-Asp-Gly)

Epitalon is a four-amino-acid synthetic peptide modelled on a pineal gland extract and studied for telomerase activity and aging biology.

10 mg vial · Once daily for about 20 days, subcutaneous

FOXO4-DRI

D-retro-inverso senolytic peptide

FOXO4-DRI is an engineered peptide that interferes with the FOXO4-p53 interaction and is studied for clearing senescent cells in animals.

10 mg vial · Once daily (community-reported), subcutaneous

GHK-Cu

Copper-binding tripeptide

GHK-Cu is a naturally occurring copper-binding tripeptide studied for skin, hair, and tissue-remodeling applications.

50 mg vial · Once daily, 5 days per week, subcutaneous (topical formulations are also used)

GHRP-2

Ghrelin-receptor agonist (growth hormone releasing peptide)

GHRP-2 is a synthetic hexapeptide that stimulates growth hormone release through the ghrelin receptor.

5 mg vial · Once daily (multiple daily doses are also described)

GHRP-6

Ghrelin-receptor agonist (growth hormone releasing peptide)

GHRP-6 is the original synthetic growth hormone releasing hexapeptide, a ghrelin-receptor agonist that also stimulates appetite.

5 mg vial · Up to 3x daily (per injection doses)

Glutathione

Endogenous antioxidant tripeptide (Glu-Cys-Gly)

Glutathione is the body's main intracellular antioxidant, a three-amino-acid peptide studied in many redox and detoxification contexts.

600 mg vial · Once daily or every other day, subcutaneous

Gonadorelin

Synthetic GnRH decapeptide

Gonadorelin is the synthetic form of hypothalamic GnRH, the signal that prompts the pituitary to release LH and FSH.

2 mg vial · Commonly reported 2-3 times weekly on non-consecutive days

hCG (Human Chorionic Gonadotropin)

Gonadotropin (LH-receptor agonist glycoprotein hormone)

hCG is a placental glycoprotein hormone that acts on the same receptor as luteinizing hormone, and it is used in fertility and male hypogonadism medicine.

5000 IU vial · Commonly reported three times weekly (for example Mon/Wed/Fri)

HGH 191AA (Somatropin)

Recombinant human growth hormone

HGH 191AA is the full 191-amino-acid recombinant growth hormone, identical to pituitary human GH and sold under the generic name somatropin.

10 IU vial · Once daily at bedtime

hMG (Human Menopausal Gonadotropin)

Gonadotropin (FSH and LH activity)

hMG is a purified urinary gonadotropin preparation containing both FSH and LH activity, 75 IU of each per vial in the US product.

75 IU vial · Commonly reported three times weekly alongside hCG

Humanin

Mitochondrial-derived peptide

Humanin is a short peptide encoded within mitochondrial DNA and studied for cell-protective and metabolic roles in aging.

10 mg vial · Twice weekly (community-reported), subcutaneous

IGF-1 LR3

Insulin-like growth factor 1 analog

IGF-1 LR3 is an engineered IGF-1 analog that binds IGF-binding proteins poorly, making it more potent than native IGF-1 in many assays.

1 mg vial · Once daily

Ipamorelin

Growth hormone secretagogue (ghrelin mimetic)

Ipamorelin is a selective growth-hormone secretagogue that stimulates the pituitary to release growth hormone.

10 mg vial · Once daily, often before bed (some reports use 1-3x daily), subcutaneous

Kisspeptin

Neuropeptide; GPR54 (KISS1R) agonist

Kisspeptin is a naturally occurring hypothalamic peptide that sits upstream of GnRH in the reproductive hormone cascade.

10 mg vial · Commonly reported once daily

KPV

Tripeptide fragment of α-MSH

KPV is the three-amino-acid C-terminal sequence of alpha-MSH, studied mainly for anti-inflammatory activity in gut and skin models.

10 mg vial · Once daily, subcutaneous

L-Carnitine

Amino-acid-derived mitochondrial fatty-acid transport cofactor

L-carnitine is a naturally occurring compound that helps move long-chain fats into mitochondria so they can be burned for energy.

200 mg vial · Once daily, subcutaneous (community-reported)

Livagen

Synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Ala)

Livagen is a four-residue peptide (lysine, glutamate, aspartate, alanine) studied by the Khavinson group, with a liver-oriented label.

20 mg vial · Once daily, subcutaneous (8-12 week courses, community-reported)

LL-37

Human cathelicidin antimicrobial peptide

LL-37 is the active fragment of the only human cathelicidin, an antimicrobial peptide that also signals to immune and epithelial cells.

5 mg vial · Once daily, subcutaneous (sometimes 5 days on, 2 off)

Mazdutide

GLP-1/glucagon dual receptor agonist

Mazdutide activates both the GLP-1 and glucagon receptors; it is approved in China and still investigational in the US.

10 mg vial · Once weekly, subcutaneous

Melanotan II

Cyclic melanocortin receptor agonist (alpha-MSH analog)

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone that has been studied for skin pigmentation and erectile response.

10 mg vial · Commonly reported once daily during a 6-8 week loading phase, then 1-2 times weekly

MGF (Mechano Growth Factor)

IGF-1 splice-variant peptide

MGF is a splice variant of the IGF-1 gene whose E-domain peptide has been studied for activating muscle stem cells after mechanical stress.

5 mg vial · Once daily

MOTS-c

Mitochondrial-derived peptide

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA that has been studied as a regulator of metabolism.

10 mg vial · Once daily, subcutaneous (community-reported)

NAD+

Coenzyme (dinucleotide)

NAD+ is an essential cellular coenzyme whose tissue levels decline with age, making it a focus of longevity research.

500 mg vial · Once daily (community-reported), subcutaneous

Ovagen

Synthetic tripeptide bioregulator (Glu-Asp-Leu)

Ovagen is a three-residue peptide (glutamate, aspartate, leucine) from the Khavinson bioregulator family, linked to liver and kidney cell research.

20 mg vial · Once daily, subcutaneous (up to 16 weeks with gradual escalation, community-reported)

Oxytocin

Neurohypophyseal nonapeptide hormone

Oxytocin is a nine-amino-acid hormone made in the hypothalamus that acts on the uterus, the breast and certain brain circuits.

5 mg vial · Commonly reported once daily

PE-22-28

Spadin-derived peptide (TREK-1 channel blocker)

PE-22-28 is a short peptide fragment derived from spadin and studied as a blocker of the TREK-1 potassium channel in depression models.

10 mg vial · Once daily, subcutaneous

PEG-MGF

Pegylated IGF-1 splice-variant peptide

PEG-MGF is MGF with attached polyethylene glycol to slow its breakdown, studied for muscle regeneration biology.

2 mg vial · Once daily

Pinealon

Synthetic tripeptide bioregulator (Glu-Asp-Arg)

Pinealon is a three-residue peptide (glutamate, aspartate, arginine) developed by the Khavinson group as a brain-oriented bioregulator.

20 mg vial · Once daily, subcutaneous, in 10-20 day courses (community-reported)

Prostamax

Synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Pro)

Prostamax is a four-residue peptide (lysine, glutamate, aspartate, proline) from the Khavinson family, associated with prostate tissue.

20 mg vial · Once daily, usually intramuscular with subcutaneous as an alternative (8-12 week courses, community-reported)

PT-141 (Bremelanotide)

Cyclic heptapeptide melanocortin receptor agonist (MC3R/MC4R)

PT-141 (bremelanotide) is a melanocortin receptor agonist that is FDA-approved for low sexual desire in premenopausal women.

10 mg vial · Labeled as needed (1.75 mg, at most one dose per 24 hours and 8 doses per month); reference charts also show daily escalation

Retatrutide

GLP-1 / GIP / glucagon triple agonist

Retatrutide is an investigational triple agonist targeting the GLP-1, GIP, and glucagon receptors.

40 mg vial · Once weekly, subcutaneous

Selank

Synthetic heptapeptide (tuftsin analog)

Selank is a synthetic heptapeptide derived from the immune peptide tuftsin and studied for anxiety-related and cognitive effects.

5 mg vial · 3x daily, intranasal

Semaglutide

GLP-1 receptor agonist

Semaglutide is a GLP-1 receptor agonist widely studied for glucose regulation and appetite.

5 mg vial · Once weekly, subcutaneous

Semax

Synthetic ACTH(4-10) heptapeptide analog

Semax is a synthetic heptapeptide built from a fragment of ACTH that is studied for effects on brain function without hormonal activity.

5 mg vial · 2-3x daily in the first half of the day, intranasal

Sermorelin

Growth hormone releasing hormone analog

Sermorelin is the first 29 amino acids of human GHRH, the shortest fragment that keeps its full biological activity.

5 mg vial · Once daily at bedtime

SS-31

Mitochondria-targeted tetrapeptide (cardiolipin-binding)

SS-31 (elamipretide) is a small peptide that concentrates in mitochondria and has been tested in several mitochondrial disease trials.

50 mg vial · Once daily, subcutaneous (the highest reported amounts are split into two injections)

Survodutide

Glucagon/GLP-1 dual receptor agonist

Survodutide is an investigational dual glucagon and GLP-1 receptor agonist being developed for obesity and fatty liver disease.

10 mg vial · Once weekly, subcutaneous

TB-500

Thymosin beta-4 fragment

TB-500 is a synthetic version of a region of the naturally occurring protein thymosin beta-4.

5 mg vial · Once daily, subcutaneous (a weekly loading pattern is also reported)

Teriparatide

Parathyroid hormone analog (PTH 1-34)

Teriparatide is the active 34-amino-acid fragment of human parathyroid hormone and is FDA-approved for osteoporosis in people at high fracture risk.

0.75 mg vial · Once daily in the labeled regimen and in cited trials

Tesamorelin

Growth hormone releasing hormone analog

Tesamorelin is a stabilized GHRH analog that is FDA-approved (Egrifta) for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.

10 mg vial · Once daily, subcutaneous

Testagen

Synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Gly)

Testagen is a four-residue peptide (lysine, glutamate, aspartate, glycine) modeled on pituitary extracts, linked in the Khavinson literature to the pituitary-gonadal axis.

20 mg vial · Once daily, subcutaneous (8-12 week courses, community-reported)

Thymosin Alpha-1

Synthetic 28-amino-acid thymic peptide

Thymosin alpha-1 is a synthetic copy of a peptide first isolated from thymic tissue, studied for its effects on T-cell and dendritic-cell function.

5 mg vial · Once daily, subcutaneous

Tirzepatide

GIP/GLP-1 dual receptor agonist

Tirzepatide is a dual agonist that activates both the GIP and GLP-1 receptors.

50 mg vial · Once weekly, subcutaneous

Vesugen

Synthetic tripeptide bioregulator (Lys-Glu-Asp)

Vesugen is a three-residue peptide (lysine, glutamate, aspartate) from the Khavinson family, associated with blood vessels and the cardiovascular system.

20 mg vial · Once daily, subcutaneous (8-12 week courses, community-reported)

Vilon

Synthetic dipeptide bioregulator (Lys-Glu)

Vilon is the two-residue peptide lysine-glutamate (Lys-Glu), developed by the Khavinson group as a thymus-related immune bioregulator.

20 mg vial · Once daily for 5 consecutive days, then about 23 days off (community-reported)

Blends

AOD-9604 + CJC-1295 + Ipamorelin 12 mg Blend

Growth-hormone axis and lipolytic-fragment blend

A three-peptide vial pairing a growth-hormone fragment (AOD-9604) with a GHRH analog (CJC-1295) and a ghrelin-mimetic secretagogue (ipamorelin).

12 mg vial · Once daily, commonly on waking or before bed on an empty stomach, subcutaneous

BPC-157 + TB-500 20 mg Blend

Tissue-repair research blend (BPC-157 + TB-500)

This blend combines BPC-157 and TB-500 in a single vial (20 mg by default, with a 10 mg size also listed), a common pairing in recovery-oriented research because the two peptides are studied for complementary roles in tissue-repair research.

20 mg vial · Once daily, subcutaneous

Cagrilintide + Semaglutide 10 mg Blend

Amylin analog + GLP-1 receptor agonist blend

Equal parts of an amylin analog and a GLP-1 receptor agonist in one vial, mirroring the fixed-ratio combination studied in clinical trials.

10 mg vial · Once weekly, subcutaneous

CJC-1295 (No DAC) + Ipamorelin 10 mg Blend

Growth-hormone axis blend

This blend pairs a GHRH analog (CJC-1295 No DAC) with a ghrelin-mimetic secretagogue (Ipamorelin) in one vial.

10 mg vial · Once daily, commonly before bed or on waking (some reports use 2x daily), subcutaneous

CJC-1295 + GHRP-2 10 mg Blend

Growth-hormone axis blend

A GHRH analog and a ghrelin-mimetic peptide combined in one vial, the same two-receptor idea behind other GH-axis blends.

10 mg vial · Once daily, commonly in the evening on an empty stomach (some protocols split it into two daily doses), subcutaneous

GLOW 70 mg Blend

Tissue-repair and skin-support blend (three peptides)

A three-peptide vial combining copper peptide GHK-Cu with BPC-157 and TB-500, two peptides common in tissue-repair research.

70 mg vial · Once daily, subcutaneous

KLOW 80 mg Blend

Tissue-repair and anti-inflammatory blend (four peptides)

The GLOW trio plus KPV: GHK-Cu, BPC-157 and TB-500 with an anti-inflammatory tripeptide in one 80 mg vial.

80 mg vial · Once daily, subcutaneous

Tesamorelin + Ipamorelin 10 mg Blend

Growth-hormone axis blend

A GHRH analog (tesamorelin) and a ghrelin-mimetic secretagogue (ipamorelin) mixed 1:1 in one vial.

10 mg vial · Once daily, commonly in the evening or before bed, subcutaneous

Tri-Heal 45 mg Blend

Tissue-repair and anti-inflammatory blend (three peptides)

TB-500, BPC-157 and KPV in one 45 mg vial, with TB-500 making up more than half the mass.

45 mg vial · Once daily, subcutaneous

Stacks

Separate vials commonly reported as used together.

CJC-1295 DAC 2 mg + Ipamorelin 5 mg (separate vials)

Stack · 2 vials

CJC-1295 DAC and ipamorelin kept in separate vials, one long-acting GHRH analog given weekly alongside a short-acting secretagogue given daily.

Ipamorelin once daily (often before bed), CJC-1295 DAC once weekly on a fixed day, subcutaneous

CJC-1295 DAC 5 mg + Ipamorelin 5 mg (separate vials)

Stack · 2 vials

CJC-1295 DAC and ipamorelin kept in separate vials, one long-acting GHRH analog given weekly alongside a short-acting secretagogue given daily.

Ipamorelin once daily (often before bed), CJC-1295 DAC once weekly on a fixed day, subcutaneous

PT-141 + Melanotan II (separate vials)

Stack · 2 vials

PT-141 and melanotan II, two melanocortin-receptor agonists, reconstituted in separate vials and used on different schedules.

PT-141 on demand (no more than once in 24 hours); melanotan II daily while loading, then 2-3x weekly, subcutaneous

TB-500 + BPC-157 (separate vials)

Stack · 2 vials

TB-500 and BPC-157 reconstituted in their own vials and used together, a pairing often reported in recovery-focused research protocols.

Daily, subcutaneous